Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies

References

• Ishizaka K, Ishizaka T Identification of IgE. J Allergy Clin Immunol. 2016;137:1646–1650.
   PubMed Web of Science ®Google Scholar
• Johansson SG The discovery of IgE. J Allergy Clin Immunol. 2016;137:1671–1673.
   PubMed Web of Science ®Google Scholar
• Oettgen HC Fifty years later: emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137:1631–1645.
   PubMed Web of Science ®Google Scholar
• Platts-Mills TA, Schuyler AJ, Erwin EA, et al. IgE in the diagnosis and treatment of allergic disease. J Allergy Clin Immunol. 2016;137:1662–1670.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11:1321–1333.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10:1033–1042.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16:491–502.
   PubMed Web of Science ®Google Scholar
• Samitas K, Delimpoura V, Zervas E, et al. Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015;24:594–601.
   PubMed Web of Science ®Google Scholar
• Sattler C, Garcia G, Humbert M. Novel targets of omalizumab in asthma. Curr Opin Pulm Med. 2017;23:56–61.
   PubMed Web of Science ®Google Scholar
• Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats I. Effects on serum IgE concentrations. Eur J Immunol. 1985;15:272–277.
   PubMed Web of Science ®Google Scholar
• Marshall JS, Bell EB. Induction of an auto-anti-IgE response in rats III. Inhibition of a specific IgE response. Immunology. 1989;66:428–433.
   PubMed Web of Science ®Google Scholar
• Marshall JS, Prout SJ, Jaffery G, et al. Induction of an auto-anti-IgE response in rats II. Effects on mast cell populations. Eur J Immunol. 1987;17:445–451.
   PubMed Web of Science ®Google Scholar
• Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol. 1994;24:415–420.
   PubMed Web of Science ®Google Scholar
• Stanworth DR, Jones VM, Lewin IV, et al. Allergy treatment with a peptide vaccine. Lancet. 1990;336:1279–1281.
   PubMed Web of Science ®Google Scholar
• Peng Z, Liu Q, Wang Q, et al. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clin Exp Allergy. 2007;37:1040–1048.
   PubMed Web of Science ®Google Scholar
• Champion BR, Stead DR, Wright P IGE CH3 Peptide Vaccine. US8722053 (2011)
   Google Scholar
• Weeratna RD, Chikh G, Zhang L, et al. Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates. Immun Inflamm Dis. 2016;4:135–147.
   PubMed Web of Science ®Google Scholar
• Wong GY, Elfassi E, Girard G, et al. A phase 1 first-in-human study (b4901001) evaluating a novel anti-ige vaccine in adult subjects with allergic rhinitis. AAAAI-2016 2016; abstr. 539. [cited 28th December 2016]. Available from: URL: http://www.jacionline.org/article/S0091-6749(15)02412-4/fulltext
   Google Scholar
• Vernersson M, Ledin A, Johansson J, et al. Generation of therapeutic antibody responses against IgE through vaccination. Faseb J. 2002;16:875–877.
   PubMed Web of Science ®Google Scholar
• Li W, Joshi MD, Singhania S, et al. Peptide vaccine: progress and challenges. Vaccines (Basel). 2014;2:515–536.
   PubMedGoogle Scholar
• Peng Z Vaccines targeting IgE in the treatment of asthma and allergy. Hum Vaccin. 2009;5:302–309.
   PubMed Web of Science ®Google Scholar
• Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov. 2007;6:404–414.
   PubMed Web of Science ®Google Scholar
• Wang CY, Walfield AM, Fang X, et al. Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine. 2003;21:1580–1590.
   PubMed Web of Science ®Google Scholar
• Ledin A, Bergvall K, Hillbertz NS, et al. Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels. Vaccine. 2006;24:66–74.
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–536.
   PubMed Web of Science ®Google Scholar
• Ma Y, Hayglass KT, Becker AB, et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med. 2007;176:439–445.
   PubMed Web of Science ®Google Scholar
• Ma Y, HayGlass KT, Becker AB, et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy. 2007;62:675–682.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Tissot A, Lechner F, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20:3104–3112.
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest. 2001;108:415–423.
   PubMed Web of Science ®Google Scholar
• Akache B, Weeratna RD, Deora A, et al. Anti-IgE Qb-VLP conjugate vaccine self-adjuvants through activation of TLR7. Vaccines (Basel). 2016;4:pii: E3.
   PubMed Web of Science ®Google Scholar
• Morsey MA, Sheppard MG, Wheeler DW Anti-IgE Vaccines. US8273356 (2012)
   Google Scholar
• T. T IgE peptide vaccine. US20150203550 (2015)
   Google Scholar
• Clark D, Shiota F, Forte C, et al. Biomarkers for non-human primate type-I hypersensitivity: antigen-specific immunoglobulin E assays. J Immunol Methods. 2013;392:29–37.
   PubMed Web of Science ®Google Scholar
• Maurer P, Bachmann FM. Immunization against angiotensins for the treatment of hypertension. Clin Immunol. 2010;134:89–95.
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3:e2547.
   PubMed Web of Science ®Google Scholar
• Cooper CL, Davis HL, Morris ML, et al. Safety and immunogenicity of CpG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136–3143.
   PubMed Web of Science ®Google Scholar
• A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. [cited 28th December 2016]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT01723254?term=NCT01723254&rank=1&sect=Xab3756
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–887.
   PubMed Web of Science ®Google Scholar
• Marseglia GL, Merli P, Caimmi D, et al. Nasal disease and asthma. Int J Immunopathol Pharmacol. 2011;24:7–12.
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Bottino C, et al. Emerging drugs for the treatment of perennial allergic rhinitis. Expert Opin Emerg Drugs. 2016;21:57–67.
   PubMed Web of Science ®Google Scholar
• Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest. 2013;144:411–419.
   PubMed Web of Science ®Google Scholar
• Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allerg. 2014;44:1371–1385.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol. 2016;138:1051–1059.
   PubMed Web of Science ®Google Scholar
• Nyborg AC, Zacco A, Ettinger R, et al. Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. Cell Mol Immunol. 2016;13:391–400.
   PubMed Web of Science ®Google Scholar
• Sheldon E, Schwickart M, Li J, et al. Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti- IgE monoclonal antibody, in subjects with atopy: a phase I study. Adv Ther. 2016;33:225–251.
   PubMed Web of Science ®Google Scholar
• Liour SS, Tom A, Chan YH, et al. Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody. Pediatr Allergy Immunol. 2016;27:446–451.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Harris JM, Boulet LP, et al. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med. 2014;6:243ra85.
   PubMed Web of Science ®Google Scholar
• Harris JM, Maciuca R, Bradley S, et al. Efficacy and safety of quilizumab in adults with allergic asthma inadequately controlled on inhaled corticosteroids and a second controller (COSTA Study). Am J Respir Crit Care Med. 2015;191:A5168.
   Web of Science ®Google Scholar
• Brightbill HD, Lin YL, Lin Z, et al. Quilizumab is an afucosylated humanized anti-M1 prime therapeutic antibody. Clin Anti-Inflamm Anti-Allergy Drugs. 2014;1:24–31.
   Google Scholar
• Harris JM, Maciuca R, Bradley MS, et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir Res. 2016;17:29.
   PubMed Web of Science ®Google Scholar